Comparison between recombinant virus assay and live virus assay on evaluating anti-HIV-1 drugs
10.3760/cma.j.issn.1003-9279.2011.01.024
- VernacularTitle:重组假病毒与活病毒法在评价抗HIV-1病毒药物中的比较
- Author:
Hui-Hui CHONG
1
;
Si-Hong XU
;
Jing-Yun LI
;
You-Chun WANG
Author Information
1. 100050,北京,中国药品生物制品检定所
- Keywords:
HIV;
Recombinant virus assay;
Reverse transcriptase inhibitors;
IDV;
NVP
- From:
Chinese Journal of Experimental and Clinical Virology
2011;25(1):73-75
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compaire results of recombinant virus assay and live virus assay on evaluateing anti-HIV-1 drugs. Methods The pseudoviruse was generated by cotransfection of the plasmid B01 containing gp160 genes and pSG3△ env plasmid. After co-incubation of pseudovirus with serially diluted drug, the EC50 and ED50 were calculated according to RLU(relative light unit) for each drug. After coincubation of live virus with serially diluted drug, the EC50 was calculated according to cytopathic effect.Results EC50 of IDV measured by the recombinant virus assay and live virus assay was 88.9 nmol/L, 89.5 nmol/L, respectively, while EC50 of NVP measured by the recombinant virus assay and live virus assay was 0. 36 μmol/L,0. 23 μmol/L, respectively. The recombinant virus assay showed good reproducibility with coefficient variation of 0, however coefficient variation of live virus assay reached to 60%. ED50 of IDV and NVP measured by the recombinant virus assay were 70.6 nmol/L and 0.62 μmol/L, respectively.Coefficient variations for IDV and NVP were 14.3% and 9.7%, respectively. Conclusion The pseudoviruses could be used in evaluating anti-HIV-1 drugs. The recombinant virus assay showed good reproducibility and could calculate not only the EC50 but also the ED50 of drugs.
